Santi et al [ 31 ] conducted a meta-analysis of 12 RCTs (n=476) of chronic PDE5 inhibitors in T2DM and concluded clear evidence of improved flow mediated dilatation and reduction of IL-6, with high-sensitivity C-reactive protein (hs-CRP) improvement just failing to reach statistical significance.
← all excerpts
Should All Men with Type 2 Diabetes Be Routinely Prescribed a Phosphodiesterase Type 5 Inhibitor?
1
—
—